

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

The Epidemiologic Transition Theory and Evidence for Cancer Transitions in the US, Select European Nations, and Japan

Omer Gersten, Ph.D.^{1,*} and Magali Barbieri, Ph.D.^{2,3}

Date: 11/25/2020

¹ University of California, San Diego Extension, Department of Bioinformatics and Biostatistics, La Jolla, California.

² University of California, Berkeley, Department of Demography, Berkeley, California.

³ French Institute for Demographic Studies (INED), Paris, France.

* Author for correspondence: Omer Gersten, University of California, San Diego Extension, Department of Bioinformatics and Biostatistics, 9600 North Torrey Pines Road, La Jolla, California 92037. Email: omer.gersten@gmail.com

Abstract

Despite cancer being a leading cause of death worldwide, scant research has been carried out on the existence of “cancer transitions,” the idea that as nations develop, they move from a situation where infectious related cancers are prominent, to one where non-infectious related cancers dominate. We use annual cause-of-death data to produce death rates for common types of cancer in select high-income countries. We find that cancer mortality patterns parallel the epidemiologic transition, which states that as countries advance, they move from a regime where infectious diseases are most common to one where non-infectious disease are most common. An implication is that the epidemiologic transition theory as originally formulated continues to be relevant despite some researchers arguing that we need additional stages beyond the original three.

Keywords: Mortality, epidemiologic transition, cancer transition, infectious disease, non-communicable disease (NCD), United States, Europe, Japan

32 Introduction

33

34 Cancer is one of the leading causes of death worldwide and because of marked declines
35 in cardiovascular disease in several countries, cancer has become the leading cause of death in
36 many high-income populations.^{1,2,3} While the important role of infection in causing certain
37 cancer types is established and quantified (2.2 million cancer cases were attributable to infection
38 in 2018),^{4,5,6} the classical view of cancer as a prime example of a “degenerative and man-made
39 disease”^{7,8,9} remains. Indeed, most global reports, including those of the World Health
40 Organization (WHO), categorize cancer as a key non-communicable disease (NCD).¹⁰

41 Abdel Omran’s seminal article on the epidemiologic transition has had a deep and wide-
42 ranging influence on a number of academic fields^{11,12} and has been cited nearly 5,000 times.¹³ In
43 his article, Omran predicted that in the third and last stage of the transition, non-communicable
44 and chronic ailments like heart disease and cancer replace infectious diseases as prime killers. In
45 this age of degenerative and man-made diseases, infectious diseases experience a “progressive
46 decline,” but do not disappear entirely.

47 Omran’s classical view, though, is overly simplified because it overlooks the fact that
48 infection is often an important cause of cancer.¹⁴ For instance, we now know that the bacterium
49 *Helicobacter pylori* (*H. pylori*), hepatitis B and C viruses, and human papillomavirus are
50 important causes of cancers of the stomach, liver, and cervix, respectively. The number of new
51 cancer cases in 2012 attributable to infectious agents was about 79% for stomach cancer, 73%
52 for liver cancer, and 100% for cervix uteri cancer.¹⁴

53 Gersten and Wilmoth¹⁵ first introduced and developed the concept of the “cancer
54 transition,” which they meant to be analogous to Omran’s epidemiologic transition. The authors
55 analyzed cancer trends in Japan from 1951 until 1997 and found that cancers with a root in
56 infectious causes were declining, while those with a root in non-infectious causes were
57 increasing. There has thus been a playing out of the epidemiologic transition within the broad
58 and complex set of diseases that define cancer.

59 Work investigating and attempting to extend the cancer transition theory has been
60 exceptionally limited, perhaps numbering no more than a few papers. One book chapter, though,
61 that has seriously engaged with the theory is that by Knaul and colleagues¹⁶ which at one point
62 presents cross-sectional data from GLOBOCAN (2008) suggesting that cancers with a root in
63 infectious causes become less prominent as many nations move along the gradient from less to
64 more developed. A similar finding has been reported by Fidler and others¹⁷ in a more recent
65 paper using a different dataset.

66 Bray and co-authors⁴ also extend the cancer transition literature. They analyze four levels
67 of the Human Development Index – a composite indicator of life expectancy, education, and
68 gross domestic product per head – to highlight cancer-specific patterns in 2008 and trends from
69 1998-2002, and to produce future burden scenarios for 2030. One of their conclusions is that
70 “The reduction in infection-related cancers seems to be offset by concomitant increases in
71 cancers related to a westernization of lifestyle and changes in tobacco consumption and the effect
72 on lung and other cancers.” (page 800).

73 The aim of the paper here, then, is to contribute to the nascent literature on cancer
74 transition theory, and in so doing, examine the relevance of Omran’s epidemiologic transition
75 theory. The paper focuses on evidence of cancer transition in the US, select European nations,
76 and Japan, differentiating between cancers with an infectious root and other cancers. We define
77 the cancer transition as the mid-point at which a country’s population moves from a situation

78 where rates of infectious-related cancers are greater than those of non-infectious cancers, to the
79 converse situation where rates of non-infectious cancers are higher.

80

81 **Results**

82

83 Figure 1 shows trends in the age-standardized death rates from infectious-related and
84 non-infectious related cancers for all ages and both sexes combined in the six countries
85 investigated here. In all countries, mortality from infectious-related cancers has declined steadily
86 throughout the time period, except for Japan. At the beginning of the study period, the age-
87 standardized death rates from cancers with a root in infectious causes ranged from about 50 per
88 100,000 in the US to 160 per 100,000 in Japan, a ratio of 1 to 3.2. Note, however, that the series
89 starts in 1959 in the former country, but in 1950 for the latter one. In Japan, the only country
90 where mortality from these cancers increased, the peak was reached at around 180 per 100,000 in
91 1955. At the end of the period (2016-2018, depending on the country), the rates range from about
92 20 per 100,000 in Norway, Sweden, England and Wales, and the US to nearly 60 per 100,000 in
93 Japan. The discontinuity in the data is most visible for Japan and France, and is due to changes in
94 the classification of liver cancer.

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120


121

122

123

124 **Figure 1. The cancer transition, both sexes combined, in Japan, select European nations,**
125 **and the US**

126
127
128



129

130 At the beginning of the study period, all countries exhibited an increasing trend in the
131 non-infectious related cancers, with a maximum reached circa 1985 in England and Wales. Most
132 of the other countries experienced a peak around 1990, or a few years later in the case of Japan.
133 In all but the US and England and Wales, mortality from non-infectious related cancers were at
134 lowest at the beginning of the study period. Initial rates varied more than for infectious-related
135 cancers, ranging from about 40 per 100,000 in Japan to about 170 per 100,000 in England and
136 Wales, a ratio of 1 to 4.25. The peak also varied from one country to another, with a minimum of
137 nearly 120 per 100,000 in Japan (from the mid-1990s to the end of the study period) up to over
138 200 per 100,000 in England and Wales (circa 1985). While the rates have remained high with
139 little signs of decline in Japan, rates for other countries have begun to decline.

140 Japan and Norway are the only two countries where trends in mortality from the two
141 groups of cancers intersect (in the late 1980s in Japan and in the mid-1950s in Norway). These
142 countries completed their cancer transition latest in the time period; on the basis of back-
143 extrapolation, it is likely that Sweden would have completed its transition a few years earlier
144 than Norway, with France, England and Wales, and the US experiencing their transitions earlier
145 than Sweden.

146 147 **Discussion**

148
149 In this study we used temporal cancer-specific mortality data to assess whether there is
150 supporting evidence of a cancer transition in the US, England and Wales, France, Norway,
151 Sweden, and Japan. Overall, there is compelling evidence supporting the cancer transition
152 theory.

153 Of the over one hundred cancers responsible for the total cancer burden, the nine cancers
154 we examined account for over two-thirds of all cancer deaths worldwide in 20181. In
155 investigating the extent of the transition from infectious to non-infectious-related cancers, we
156 have identified specific time points when Japan and Norway had their transitions (when the
157 trends converge) and speculated on the timing of the other nations studied. While all six
158 countries selected are all classified as high-income, they are considerably diverse geographically,
159 politically, and culturally, yet their cancer patterns are quite similar.

160 Visually, Japan exhibits the most obvious cancer transition in the countries we examined
161 since its trends intersect later in the time period for which we have recorded data and most
162 closely resembles an “X” pattern. Norway is the only other country where a cancer transition
163 cross-over is visible, but it is easy to imagine that similar intersections would be observed
164 elsewhere, were additional historical data available. If Japan might be considered a “laggard” in
165 terms of its cancer transition, the US or England and Wales might be considered “forerunners,”
166 since their transitions appear to have taken place in the first half of the twentieth century, prior to
167 mortality data becoming available if one extrapolates back from visible trends.

168 We can go further in our description of cancer transitions by making some
169 generalizations about their evolution: 1) initially, infectious-related cancer mortality rates are
170 high and non-infectious-related cancer mortality are low; 2) then, infectious-related cancer
171 mortality starts declining, while non-infectious cancer mortality increases, 3) subsequently,
172 infectious-related cancer mortality reaches a low level while non-infectious cancer mortality
173 starts declining after reaching its peak.

174 Of primary importance in our paper was the grouping and analysis of infectious-related
175 versus non-infectious related cancers to identify signs of cancer transition. A caveat to such an

176 analysis is the extent to which the overall trends mask some of the underlying diversity in
177 individual cancers by sex (see Supplementary Figures 1-2). Still, despite concealing individual
178 heterogeneity, grouping cancers with more or less infectious-orientated etiologies, shows a
179 concise picture of cancer transitions.

180 To conceptualize the cancer transition that occurs as nations develop, we apply elements
181 of Omran's theory of the epidemiologic transition.⁷ Omran proposed that there are three stages in
182 the epidemiologic transition, the last being a move to the "age of degenerative and man-made
183 diseases" where illnesses like stroke and cancer rise in prominence as infectious diseases like
184 malaria, tuberculosis, and smallpox become less common. We consider Omran's understanding
185 at the time of cancer as a non-communicable/non-infectious-related disease the "classical view"
186 of cancer's etiology. In the last stage explicated by Omran, infectious diseases are increasingly
187 brought under control, but not entirely. Historically, infectious diseases tended to strike at
188 younger ages, and when these diseases were better brought under control people lived to
189 increasingly older ages when non-communicable diseases tended to strike.

190 Some researchers have attempted to extend Omran's three-stage theory by proposing a
191 "fourth stage" or even "fifth stage" of the epidemiologic transition.^{8,36,37} For instance, Olshansky
192 and Ault³⁷ postulated that there's a fourth stage of the transition that they term the "age of
193 delayed degenerative diseases" in which major causes of death are still with us, but the risk of
194 dying from those illnesses is redistributed to older ages. Like many others during their time and
195 continuing to this day,⁸⁻¹⁰ Olshansky and Ault adopt the classical view of cancer as a non-
196 communicable disease.

197 Emerging mainly from the anthropological literature is the idea that we are in a "third
198 transition," not to be confused with the "stages" of Omran's epidemiologic transition.^{38,39}
199 According to this literature, the first transition is one that predates the first stage described by
200 Omran, and occurred in the Neolithic period about 10,000 years ago. Authors writing on this
201 topic also state that at about this time there was a shift marked by the emergence of many
202 infectious diseases. The whole of Omran's epidemiologic transition is considered to be the
203 second transition, and in the third transition there are emerging infectious diseases (e.g., HIV)
204 and a reemergence of infectious diseases (e.g., tuberculosis), many of which are multiple
205 antibiotic resistant.

206 Even with emerging diseases like covid-19, deaths due to cancer, in the US at least, are
207 far greater than those caused by infectious diseases. At the time of the writing of this paper,
208 covid-19, which was first identified in December 2019, has so far killed about 250,000
209 Americans,⁴⁰ but scientists have developed a vaccine. Influenza and pneumonia, which kill
210 people year after year and are also infectious, caused about 55,000 deaths in the US in 2017.⁴¹ In
211 contrast, about 600,000 people died of cancer in that same year and country⁴¹, and deaths due to
212 infectious sources, for the US from 1980 to 2014, only accounted for a small portion (5.4%) of
213 total deaths⁴². These figures, along with the fact that many so-called "new" infectious diseases
214 are actually hundreds if not thousands of years old,⁴³ argue against a new stage of the
215 epidemiologic transition based on emerging and re-emerging infectious diseases.

216 While some proposed extensions of Omran's epidemiologic transition have made useful
217 contributions to the literature, they do not grapple with the cancer transition theory as we have
218 laid out in this paper. What many authors have not realized is that a number of widespread
219 cancers are mainly caused by infectious agents. To wit, *H. pylori* is a cause of stomach cancer,
220 the human papillomavirus is a necessary, albeit insufficient, cause of cervix uteri cancer, and
221 hepatitis B and C viruses are causes of liver cancer.¹⁴

222 As regards *H. pylori*, over half of the world’s population in 2015 were infected with the
223 bacterium⁴⁴, but only a small fraction of those infected will go on to develop stomach cancer¹⁴.
224 *H. pylori*’s prevalence is declining in most countries of the world^{45,46} not through any specific
225 measures, but as a result of general improvements in sanitation, housing conditions, access to
226 clean water, food availability and freshness, and reduced salt intake.^{15,47,48}

227 The human papillomavirus is transmitted sexually, with the majority of sexually active
228 individuals of both sexes acquiring it at some point during their lifetime.⁴⁹ Prior to the vaccine
229 becoming available in 2006,^{50,51} screening and treatment were the only means to reduce cervical
230 cancer incidence and mortality.⁵² Research is continuing into creating more affordable vaccines,
231 which will especially help less developed countries where current levels of vaccination are a
232 fraction of what they are in more developed countries.^{51,53} Reductions of cervical cancer will
233 only be evident decades after vaccination, but a surrogate for cervical cancer – high-grade
234 cervical intra-epithelial neoplasia – has shown significant reductions in populations with high
235 vaccine coverage.⁵⁴

236 The last cancer with a root in infectious causes that we investigated is liver cancer, and
237 persistent hepatitis B and C viruses together account for about 90% of hepatocellular carcinoma,
238 the most common form of liver cancer.⁵⁵ A vaccine for hepatitis B has been available since the
239 early-1980s, and was progressively administered to infants as part of national childhood
240 immunization programs in 90 countries in the late 1980s and 1990s. Hepatitis B decreases have
241 been observed in most countries.^{56,57} Currently there is not a vaccine for hepatitis C, but there is
242 antiviral treatment which cures about 90% of those infected with the virus.⁵⁸ To summarize,
243 there are reasons to expect that mortality from cancers with a root in infectious causes will
244 decline even further in the future.

245 As far as the trends for the combined non-infectious related cancers are concerned, there
246 was a plateauing or decline in five of the six countries starting between 1985-2000 (with
247 Sweden’s decline occurring in the early 1970s). The pattern of risk factors over the last few
248 decades in these countries for the individual cancers are mixed. A decline in total physical
249 activity has been documented in Japan^{59,60} and the US.⁶¹ Although there doesn’t appear to be
250 country-specific data for the other nations we examine, one study found that in high-income
251 Western countries, between 2001 and 2016, physical inactivity increased by 5%.⁶² Another
252 important trend is that Japan and France seem to have largely resisted
253 “Westernization”/degradation of their diets,^{63,64} but not the US⁶⁵ and England and Wales⁶⁶. There
254 is not enough literature on the diets in Norway and Sweden to determine the extent to which their
255 diets have changed.

256 The average body mass index (BMI) in 2014 for Japanese men and women was in the
257 “normal” range, but for the other countries, either men or women, or both, have average BMIs in
258 the “overweight” category.⁶⁷ Alcohol consumption from 1990 - 2016 for both men and women
259 was nearly level in the US and Japan, slightly increased in England and Wales, Norway, and
260 Sweden, and declined markedly in France.⁶⁸ A substantial, positive trend, has been a reduction in
261 smoking prevalence that has resulted in lower lung cancer rates some thirty to forty years later.⁶⁹

262 Importantly, the ability to both detect and treat some cancers has improved dramatically,
263 such as for cancers of the breast⁷⁰ and colorectum.⁷¹ Prostate-specific antigen (PSa) screening
264 remains controversial,^{72,73} but treatment for prostate cancer has become more effective.⁷⁴
265 Unfortunately, esophageal cancer is typically diagnosed late in its course when it’s more difficult
266 to treat, but in cases where early esophageal cancer is detected, evolving therapies have

267 improved the cure rate.⁷⁵ For pancreatic cancer, even though there has been advances in imaging
268 and surgery, mortality rates have decreased little as a result.⁷⁶

269 Based on our findings, we confirm and extend the hypothesis of Gersten and Wilmoth¹⁵
270 that the cancer transition can be considered analogous to the epidemiologic transition. Put
271 another way, one can say that the cancer transition “parallels” the epidemiologic transition, in
272 that there is an epidemiologic transition also within the complex system of cancers linked to
273 specific causes. This linkage between the epidemiologic and cancer transition theories is
274 presented schematically in Figure 2.

275 A main implication of our analysis, then, is that while Omran’s theory does not apply to
276 part of the third stage of cancer transitions, in which non-infectious related cancers have peaked
277 and have in some settings, begun to decline, cancer remains bound in epidemiologic transition
278 theory. Indeed, the theory continues to remain a very useful framework for understanding
279 fundamental mortality patterns for cancer, a leading cause of death worldwide.

280

281

282

283 **Figure 2. Comparison of the epidemiologic transition and cancer transition theories**

284

Major Causes of Death

	Before – infectious disease	After – non-infectious disease
Epidemiologic transition	Malaria Tuberculosis Smallpox	Cancer Heart disease Stroke
Cancer transition	Stomach (<i>H. pylori</i>) Liver (hepatitis B and C viruses) Cervix uteri (human papillomavirus)	Lung, pancreas (smoking) Breast (hormonal and physical activity) Colorectum (Western lifestyle)

285

286

287

Methods

288

289

290 We selected the countries in our analysis based on the availability, detail and quality of
291 their cause-of-death records, and how far back the data series extended. Annual cause-of-death
292 data were obtained directly from national statistics offices and the World Health Organization
293 (WHO) Mortality Database¹⁸ and combined with life table series from the Human Mortality
294 Database¹⁹ to compute age-standardized death rates for common types of cancer in six countries
295 over extended periods of time: the United States (1959-2017), England and Wales (1950-2018),
296 France (1958-2016), Norway (1951-2016), Sweden (1952-2016), and Japan (1950-2016). The
297 European 2013 standard population was used to account for differences in age structure across
298 the six countries.

299 Our analysis presents results for all ages combined and for nine cancers grouped
300 according to their known etiology, separating those with a root in infectious causes from those

301 with non-infectious causes. Cancers with a root in infectious causes included stomach, liver, and
302 cervical cancer, which together accounted for 19.7% of worldwide cancer deaths in 2018¹

303 Concerning the six cancers with a root in non-infectious causes that we analyze, those
304 cancers and their main causes are: lung – smoking;²⁰ pancreatic – smoking;^{21,22} esophageal –
305 smoking and drinking;^{23,24} breast – reproductive/hormonal and physical activity,^{25,26} colorectal –
306 Western lifestyle;^{27,28} and prostate – age, ethnicity, and family history.²⁹⁻³¹ Together, these
307 cancers accounted for 47.6% of worldwide cancer deaths in 2018.¹

308 The International Classification of Diseases (ICD), implemented by all study countries
309 during the time period under consideration, has gone through numerous revisions, from the sixth
310 in 1950 to the tenth currently. These ICD revisions introduce some disruptions in the data series.
311 However, as documented in the literature, cancer as a disease is much better defined than many
312 others and these disruptions are small enough that a general picture of the overall trends emerges
313 very clearly.^{32,33} Similarly, differences in diagnostic and coding practices do not appear to be
314 large enough across countries to bias international comparisons in cancer mortality trends.^{34,35}

315

316

317 **Acknowledgements**

318

319 We are grateful to Freddie Bray and Ken Wachter for their comments on a draft of this paper,
320 and we wish to thank Yuan Zhang for organizing a synchronous, virtual session for the 2020
321 Population Association of America Annual Meeting at which this paper was presented orally.
322 Lastly, we thank Miriam Rauch for providing vital support.

323

324

325 **Conflicts of interest**

326

327 We declare no competing interests.

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347 **References**

- 348
- 349 ¹ Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., et al. (2018). Global Cancer
350 Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
351 Cancers in 185 Countries. *CA A Cancer Journal for Clinicians*: 68(6):394-424.
- 352 ² Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., et al. (2018).
353 Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality
354 for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries
355 and territories. *Lancet*: 392:2052-2090.
- 356 ³ Ezzati, M., Obermeyer, Z., Tzoulaki, I., Mayosi, B. M., Elliot, P., et al. (2015). Contributions of
357 risk factors and medical care to cardiovascular mortality trends. *Nature Reviews*
358 *Cardiology*: 12(9): 508-30.
- 359 ⁴ Bray, F., Jemal, A., Grey, N., Ferlay, J., and Forman, D. (2012). Global Cancer Transitions
360 According to the Human Development Index (2008-2030): A Population-Based Study.
361 *The Lancet Oncology*: 13(8):790-801.
- 362 ⁵ Oh, J.-K. and Weiderpass, E. (2014). Infection and Cancer: Global Distribution and Burden of
363 Diseases. *Annals of Global Health*: 80:384-392.
- 364 ⁶ de Martel, C., Georges, D., Bray, F., Ferlay, J., and Clifford, G.M. (2020). Global burden of
365 cancer attributable to infections in 2018: a worldwide incidence analysis. *Lancet Glob*
366 *Health*: 8(2):e180-e190.
- 367 ⁷ Omran, A. R. (1971). The Epidemiologic Transition: A Theory of the Epidemiology of
368 Population Change. *The Milbank Quarterly*: 49(4):509-38.
- 369 ⁸ Gaziano, J. M. (2010). Fifth Phase of the Epidemiologic Transition: The Age of Obesity and
370 Inactivity. *JAMA*: 303(3):275-276.
- 371 ⁹ Global Burden of Disease Cancer Collaboration. (2018). *JAMA Oncology*: 4(11):1553-1568.
- 372 ¹⁰ World Health Organization (WHO). (2014). Global status report on noncommunicable
373 Disease 2014. Accessed on May 27, 2019: [https://www.who.int/nmh/publications/ncd-](https://www.who.int/nmh/publications/ncd-status-report-2014/en/)
374 [status-report-2014/en/](https://www.who.int/nmh/publications/ncd-status-report-2014/en/)
- 375 ¹¹ Zuckerman, M. K., Harper, K. N., Barrett, R., and Armelagos, G. J. (2014). The Evolution of
376 Disease: Anthropological Perspectives on Epidemiologic Transitions. *Global Health*
377 *Action*: 7:23303.
- 378 ¹² Weisz, G. and Olszynko-Gryn, J. (2009). The Theory of Epidemiologic Transition: the Origins
379 of a Citation Classic. *Journal of the History of Medicine and Allied Sciences*: 65(3):287-
380 326.
- 381 ¹³ Google Scholar. Number of citations for “Omran, A. R. (1971). The Epidemiologic Transition:
382 A Theory of the Epidemiology of Population Change. *The Milbank Quarterly*: 49(4):509-
383 38.” Accessed on January 15, 2020: <https://scholar.google.com>.
- 384 ¹⁴ Plummer, M., de Marel, C., Vignat, J., Ferlay, J., Bray, F., et al. (2016). Global Burden of
385 Cancers Attributable to Infections in 2012: A Synthetic Analysis. *Lancet Global Health*:
386 4:e609-16.
- 387 ¹⁵ Gersten, O. and Wilmoth, J. R. (2002). The Cancer Transition in Japan since 1951.
388 *Demographic Research*: 7(5):271-306.
- 389 ¹⁶ Knaul, F. M., Adami, H.-O., Adebamowo, C., Arreola-Ornelas, H., Berger, A. J., et al. (2012).
390 The Global Cancer Divide: An Equity Imperative. Chapter 2 in *Closing the Cancer*
391 *Divide: An Equity Imperative*: 29-70.
- 392 ¹⁷ Fidler, M. M., Bray, F., and Soerjomataram, I. (2018). The global cancer burden and human

- 393 development: A review. *Scandinavian Journal of Public Health*: 46(1):27-36.
- 394 ¹⁸ World Health Organization (WHO) Mortality Database. Accessed on January 31, 2020:
395 https://www.who.int/healthinfo/mortality_data/en/
- 396 ¹⁹ Human Mortality Database. Accessed on January 31, 2020: <https://www.mortality.org>.
- 397 ²⁰ Schwartz, A. G. and Cote, M. L. (2016). Ahmad, A. and Gadeel, S. (eds). *Lung Cancer and*
398 *Personalized Medicine. Epidemiology of Lung Cancer. Advances in Experimental*
399 *Medicine and Biology*: 893: 21-41.
- 400 ²¹ Rawla, P., Sunkara, T., and Gaduputi, V. (2019). *Epidemiology of Pancreatic Cancer: Global*
401 *Trends, Etiology and Risk Factors. World Journal of Oncology*: 10(1):10-27.
- 402 ²² Ilic, M. and Ilic I. (2016). *Epidemiology of pancreatic cancer. World Journal of*
403 *Gastroenterology*: 22(44):9694-9705.
- 404 ²³ Murphy, G., McCormack, V., Abedi-Ardekani, B., Arnold, M., Camargo, M. C., et al. (2017).
405 *International cancer seminars: a focus on esophageal squamous cell carcinoma. Annals of*
406 *Oncology*: 28:2086-2093.
- 407 ²⁴ Dong, J. and Thrift, A. P. (2017). *Alcohol, smoking and risk of oesophago-gastric cancer.*
408 *Best Practice & Research Clinical Gastroenterology*: (31)5:509-517.
- 409 ²⁵ Winters, S., Martin, C., Murphy, D., and Shokar, N. K. (2017). *Breast Cancer and*
410 *Epidemiology, Prevention, and Screening. Progress in Molecular Biology and*
411 *Translational Science*: 151:1-32.
- 412 ²⁶ Rojas, K. and Stuckey, A. (2016). *Breast Cancer Epidemiology and Risk Factors. Clinical*
413 *Obstetrics and Gynecology*: 59(4):651-672.
- 414 ²⁷ Hadjipetrou, A., Anyfantakis, D., Galanakis, C. G., Kastanakis, M., and Kastanakis, S.
415 (2017). *Colorectal cancer, screening and primary care: A mini literature review. World*
416 *Journal of Gastroenterology*: 23(33):6049-6058.
- 417 ²⁸ Song, M., Garrett, W. S., and Chan, A. T. (2015). *Nutrients, Foods, and Colorectal Cancer*
418 *Prevention. Gastroenterology*: 148:1244-1260.
- 419 ²⁹ Rawla, P. (2019). *Epidemiology of Prostate Cancer. World Journal of Oncology*: 10(2):63-89.
- 420 ³⁰ Alvarez-Cubero, M. S., Pascual-Geler, M., Rivas, A., Javier-Martinez, L., Saiz, M. et al.
421 (2015). *Lifestyle and dietary factors in relation to prostate cancer risk. International*
422 *Journal of Food Sciences and Nutrition*: 66(7):805-810.
- 423 ³¹ Perez-Cornago, A., Key, T. J., Allen, N. E., Fensom, G. K., Bradbury, K. E., et al., (2017).
424 *Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort*
425 *study*: 117:1562:1571.
- 426 ³² Percy, C., and Dolman, A. (1978). *Comparison of the coding of death certificates related to*
427 *cancer in seven countries. Public Health Reports*, 93(4), 335-350.
- 428 ³³ Hoel, D. G., Ron, E., Carter, R., and Mabuchi, K. (1993). *Influence of death certificate errors*
429 *on cancer mortality trends. Journal of the National Cancer Institute*, 85(13), 1063-1068.
- 430 ³⁴ Percy, C., Stanek 3rd, E., and Gloeckler, L. (1981). *Accuracy of cancer death certificates and*
431 *its effect on cancer mortality statistics. American Journal of Public Health*, 71(3), 242-
432 250.
- 433 ³⁵ Kelson, M., and Farebrother, M. (1987). *The effect of inaccuracies in death certification and*
434 *coding practices in the European economic community (EEC) on international cancer*
435 *mortality statistics. International Journal of Epidemiology*, 16(3), 411-414.
- 436 ³⁶ Hazra, N.C. and Gulliford, M. (2017). *Evolution of the “Fourth Stage” of the Epidemiologic*
437 *Transition in People Aged 80 Years and Over: Population-Based Cohort Study Using*
438 *Electronic Health Records. Population Health Metrics*: 15(1):18.


- 439 ³⁷ Olshansky, S. J. and Ault, A. B. (1986). The Fourth Stage of the Epidemiologic Transition:
440 The Age of Delayed Degenerative Diseases. *Milbank Quarterly*: 64(3): 355-91.
- 441 ³⁸ Armelagos, G. J., Brown, P. J., and Turner, B. (2005). Evolutionary, Historical and Political
442 Economic Perspectives on Health and Disease. *Social Science & Medicine*: 61:755-765.
- 443 ³⁹ Barrett, R., Kuzawa, C. W., McDade, T., and Armelagos, R. (1998). Emerging and Re-
444 Emerging Infectious Diseases: The Third Epidemiologic Transition. *Annual Review of*
445 *Anthropology*: 27:247-71.
- 446 ⁴⁰ Johns Hopkins University of Medicine (2020). Johns Hopkins University of Medicine
447 Coronavirus Resource Center. Accessed on November 17, 2020:
448 <https://coronavirus.jhu.edu/map.html>
- 449 ⁴¹ Heron, M. (2019). Deaths: Leading Causes for 2017. Department of Health and Human
450 Services: National Vital Statistics Report: 68(6):1-77.
- 451 ⁴² Hansen, V., Oren, E., Dennis, L. K., Brown, H. E. (2016). Infectious Disease Mortality Trends
452 in the United States, 1980-2014. *Journal of the American Medical Association*: 316(20):
453 2149-2151.
- 454 ⁴³ Olshansky, S. J., Carnes, B. A., Rogers, R. G., and Smith, L. (1998) Emerging infectious
455 diseases: the Fifth stage of the epidemiologic transition? *World Health Statistics*
456 *Quarterly*, 51:207-217.
- 457 ⁴⁴ Hooi, J. K. Y., Lai, W. Y., Ng, W. K., Suen, M. M. Y., Underwood, F. E., et al. (2017).
458 Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-
459 Analysis. *Gastroenterology*: 153:420-429.
- 460 ⁴⁵ Eusebi, L. H., Zagari, R. M., and Bazzoli, F. (2014). Epidemiology of *Helicobacter pylori*
461 infection. *Helicobacter*: (Suppl 1)19:1-5.
- 462 ⁴⁶ Peleteiro, B., Bastos, A., Ferro, A., and Lunet, N. (2014). Prevalence of *Helicobacter pylori*
463 Infection Worldwide: A Systematic Review of Studies with National Coverage: 59:1698-
464 1709.
- 465 ⁴⁷ Brown, L. M. (2000). *Helicobacter pylori*: Epidemiology and Routes of Transmission.
466 *Epidemiologic Reviews*: 22(2):283-297.
- 467 ⁴⁸ Reai, N., Behrouz, B., Zahri, S., and Latifi-Navid, S. (2016). *Helicobacter pylori* Infection and
468 Dietary Factors Act Synergistically to Promote Gastric Cancer. *Asian Pacific Journal of*
469 *Cancer Prevention*: 17(3):917-921.
- 470 ⁴⁹ Forman, D., de Martel, C., Lacey, C. J., Soerjomataram, I., Lortet-Tieulent, J., et al. (2012).
471 Global Burden of Human Papillomavirus and Related Diseases. *Vaccine*: 30 Suppl 5:
472 F12:F23.
- 473 ⁵⁰ Capua, T., Katz, J. A., and Bocchini, J. A. (2013). Update on adolescent immunizations:
474 selected review of US recommendations and literature. *Current Opinion in Pediatrics*:
475 25:397-406.
- 476 ⁵¹ Barra, F., Maggiore, U. L. R., Bogani, G., Ditto, A., Signorelli, M., et al. (2019). New
477 prophylactics human papilloma virus (HPV) vaccines against cervical cancer. *Journal of*
478 *Obstetrics and Gynecology*: 39(1):1-10.
- 479 ⁵² Vaccarella, S., Franceschi, S., Engholm, G., Lonnberg, S., Khan, S., et al., (2014). 50 years of
480 screening in the Nordic countries: quantifying the effects on cervical cancer incidence.
481 *British Journal of Cancer*: 111:965-969.
- 482 ⁵³ de Martel, C., Plummer, M., Vignat, J., and Franceschi, S. (2017). Worldwide burden of
483 cancer attributable to HPV site, country and HPV type. *International Journal of Cancer*:
484 141:664-670.

- 485 ⁵⁴ Stanley, M. (2017). Tumour virus vaccines: hepatitis B virus and human papillomavirus.
486 *Philosophical Transactions of the Royal Society B*: 372:20160268.
- 487 ⁵⁵ Sayiner, M., Golabi, P., and Younossi, Z. M. (2019). Disease Burden of Hepatocellular
488 Carcinoma: A Global Perspective: 64:910-917.
- 489 ⁵⁶ Kao, J.-H. (2015). Hepatitis B vaccination and prevention of hepatocellular carcinoma. *Best
490 Practice & Research Clinical Gastroenterology*: 29(6):907-917.
- 491 ⁵⁷ Ott, J. J., Horn, J., Krause, G., and Mikolajczyk, R. T. (2017). Time trends of chronic HBV
492 infection over prior decades – A global analysis. *Journal of Hepatology*: 66:48-54.
- 493 ⁵⁸ Ward, J. W. and Hinman, A. R. (2019). What Is Needed to Eliminate Hepatitis B Virus and
494 Hepatitis C Virus as Global Health Threats. *Gastroenterology*: 156:297-310.
- 495 ⁵⁹ Koba, S., Tanaka, H., Maruyama, C., Tada, N., Birou, S., et al. (2011). Physical Activity in the
496 Japan Population: Association with Blood Lipid Levels and Effects in Reducing
497 Cardiovascular and All-Cause Mortality. *Journal of Atherosclerosis Thrombosis*: 18(10):
498 833-845.
- 499 ⁶⁰ Tanaka, S. (2019). Status of Physical Activity in Japanese adults and children. *Annals of
500 Human Biology*: 46(4): 305-310.
- 501 ⁶¹ Ozemek, C, Lavie, C. J. and Rognmo, O. (2019). Global Physical Activity Levels - Need for
502 Intervention. *Progress in Cardiovascular Diseases*: 62(2): 102-107.
- 503 ⁶² Guthold, R., Stevens, G. A., Riley, L. M., and Bull, F.C. (2018). Worldwide trends in
504 insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-
505 based surveys with 1.9 million participants. *Lancet Global Health*: 6(10): e1077-e1086.
- 506 ⁶³ Drewnowski, A. and Popkin, B. M. (1997). The Nutrition Transition. *Nutrition Reviews*:
507 55(2):31-43.
- 508 ⁶⁴ Gerber, M. (2016). Implementing the Mediterranean Diet: A French Perspective and
509 Comparisons with Other Mediterranean Countries. *Mediterranean Diet*, Romagnolo,
510 D.F., and Selmin, O.I. (eds.) Springer International Publishing: Switzerland.
- 511 ⁶⁵ Hariharan, D. H., Vellanki, K., and Kramer, H. (2015). The Western Diet and Chronic Kidney
512 Disease. *Current Hypertension Reports*: 17(3):16.
- 513 ⁶⁶ Reid, M. and Hammersley, R. (2016). Is the British diet improving? *Nutrition Bulletin*,
514 41:360-364.
- 515 ⁶⁷ NCD Risk Factor Collaboration. (2016). Trends in adult body-mass index in 200 countries
516 from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with
517 19.2 million participants. *Lancet*: 387: 1377-1396.
- 518 ⁶⁸ GBD 2016 Alcohol Collaborators. (2018). Alcohol use and burden for 195 countries and
519 territories 1990 -- 2016: a systematic analysis for the Global Burden of Disease Study
520 2016: *The Lancet*: 392:1015-35.
- 521 ⁶⁹ Islami, F., Torre, L. A. and Jemal, A. (2015). Global trends of lung cancer mortality and
522 smoking prevalence. *Translational Lung Cancer Research*: 4(4):327-338.
- 523 ⁷⁰ Zurrada, S. and Veronesi, U. (2014). Milestones in Breast Cancer Treatment. *The Breast
524 Journal*: 21(1): 3-12.
- 525 ⁷¹ Bray, C., Bell, L. N., Liang, H., Collins, D. and Yale, S. H. (2017). Colorectal Cancer
526 Screening: *Wisconsin Medical Journal*: 116(1):27-33.
- 527 ⁷² Catalona, W. J. (2018). Prostate Cancer Screening: *Medical Clinics of North America*: 102(2):
528 199-214.
- 529 ⁷³ Filella, X., Albaladejo, M. D., Allue, J. A., Castano, M. A., Morell-Garcia, D. et al., (2019).
530 Prostate Cancer Screening: Guidelines Review and Laboratory Issues: *Clinical Chemistry*

531 and Laboratory Medicine: 57(10): 1474-1487.
532 ⁷⁴ Teo, M. Y., Rathkopf, D. E., and Kantoff, P. (2019). Treatment of Advanced Prostate Cancer:
533 Annual Review of Medicine: 70:479-99.
534 ⁷⁵ Alsop, B.R., and Sharma, P. (2016). Esophageal Cancer. Gerontology Clinics of North
535 America: 45(3):399-412.
536 ⁷⁶ Lindquist, C. M., Miller, F. H., Hammond, N. A., Nikolaidis, P. (2018). Pancreatic cancer
537 screening. Abdominal Radiology: 43: 264-272.
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568

569 **Supplementary Figure 1. Age-standardized death rates for the most common cancers over**
570 **time, men, in Japan, select European nations, and the US**


571



572

573 **Supplementary Figure 2. Age-standardized death rates for the most common cancers over**
574 **time, women, in Japan, select European nations, and the US**

575



576